Fast Five Quiz: Gout and Pseudogout

Herbert S. Diamond, MD


December 04, 2019

According to ACP guidelines, high-quality evidence showed no difference between low-dose febuxostat and allopurinol for gout flares. However, febuxostat is associated with higher costs than allopurinol. The most common adverse effect associated with allopurinol is rash. The most common adverse effects associated with febuxostat are abdominal pain, diarrhea, and musculoskeletal pain.

Also according to ACP guidance, low-dose colchicine is recommended when using the medication to treat acute gout. Evidence suggests that lower doses (1.2 mg followed by 0.6 mg 1 hour later) are as effective as higher doses (1.2 mg followed by 0.6 mg/h for 6 hours) for pain management, and are associated with fewer adverse gastrointestinal effects.

The ACP recommends against the use of long-term urate-lowering therapy in most patients after an initial gout attack and in patients with infrequent attacks. Although urate-lowering therapy has shown efficacy in shorter durations, the benefits of long-term use after a single or infrequent gout attacks remain unclear.

The ACP found insufficient evidence to recommend various dietary changes or supplements. Diet modifications alone are rarely able to lower uric acid levels sufficiently to prevent accumulation of urate, although they may help lessen the triggers of acute gout attacks.

Read more about the treatment of gout and pseudogout.

This Fast Five Quiz was excerpted and adapted from the Medscape Drugs & Diseases article Gout and Pseudogout.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.